AzTrials
AzTrials

Tourette SyndromePhase 3ARTISTS2NCT03571256

A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)

A Phase 3 study testing TEV-50717 in people with Tourette Syndrome, run by Teva Branded Pharmaceutical Products R&D, Inc. at 56 sites in 10 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Standard placebo-controlled, double-blind study design (TEV-50717 [low dose and high dose] vs. placebo in a 1:1:1 ratio) was chosen to determine whether study drug treatment results in a statistically significant effect on the tics in participants with TS. Read more about this study

Who is it for?
Ages 6 to 16 years
Conditions the study is for
Tourette Syndrome
What is being tested?
TEV-50717
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
158 participants
Where
56 sitesin 10 countries
Study dates
31 May 2018to 9 Dec 2019
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 16 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Participant weighs at least 44 pounds (20 kg) at baseline.
  • Participant meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5™) diagnostic criteria for TS and, in the opinion of the investigator, participant, and parent/legal guardian, the participant's active tics are causing distress or impairment.
  • Participant has a TTS of 20 or higher on the YGTSS at screening and baseline.
  • Participant is able to swallow study medication whole.
  • -Additional criteria apply, please contact the investigator for more information

Who cannot join

  • Participant has a neurologic disorder other than TS that could obscure the evaluation of tics.
  • The participant 's predominant movement disorder is stereotypy (coordinated movements that repeat continually and identically) associated with autism spectrum disorder.
  • Participant has clinically significant depression at screening or baseline.
  • Participant has a history of suicidal intent or related behaviors within 2 years of screening
  • Participant has a history of a previous actual, interrupted, or aborted suicide attempt.
  • Participant has a first-degree relative who has completed suicide.
Show all 13Show fewer
  • Participant has a confirmed diagnosis of bipolar disorder, schizophrenia, or another psychotic disorder.
  • Participant has received Comprehensive Behavioral Intervention for Tics for TS or Cognitive Behavioral Therapy for obsessive-compulsive disorder (OCD) within 4 weeks of screening.
  • Participant has received treatment with deep brain stimulation, transmagnetic stimulation, or transcranial direct current stimulation within 4 weeks of the screening visit for reduction of tics.
  • Participant has a history of torsades de pointes, congenital long QT syndrome, bradyarrhythmias, or uncompensated heart failure.
  • Participant has participated in an investigational drug or device study and received investigational medicinal product (IMP)/intervention within 30 days or 5 drug half-lives of baseline, whichever is longer.
  • Participant is a pregnant or lactating female, or plans to be pregnant during the study.
  • -Additional criteria apply, please contact the investigator for more information

Trial locations and contacts

56 sites in 10 countries.

56 sites in 10 countries

United States19 sites
  • Teva Investigational Site 060-0165

    Ann Arbor, Michigan, 48105

  • Teva Investigational Site 060-0168

    Atlanta, Georgia, 30329

  • Teva Investigational Site 060-0170

    Bridgeton, Missouri, 63044

  • Teva Investigational Site 060-0169

    Charleston, South Carolina, 29414-5834

  • Teva Investigational Site 060-0155

    Chicago, Illinois, 60612

  • Teva Investigational Site 060-0164

    Chicago, Illinois, 60634

  • Teva Investigational Site 060-0162

    Everett, Washington, 98201-4077

  • Teva Investigational Site 060-0163

    Fort Worth, Texas, 76104

  • Teva Investigational Site 060-0160

    Gainesville, Florida, 32608

  • Teva Investigational Site 060-0166

    Gulf Breeze, Florida, 32561-4458

  • Teva Investigational Site 060-0152

    Indianapolis, Indiana, 46256

  • Teva Investigational Site 060-0158

    Louisville, Kentucky, 40202

  • Teva Investigational Site 060-0157

    Memphis, Tennessee, 38157

  • Teva Investigational Site 060-0161

    Miami, Florida, 33136-2107

  • Teva Investigational Site 060-0156

    Nashville, Tennessee, 37232-2551

  • Teva Investigational Site 060-0154

    New York, New York, 10036

  • Teva Investigational Site 060-0151

    Orlando, Florida, 32801

  • Teva Investigational Site 060-0153

    Orlando, Florida, 32819

  • Teva Investigational Site 060-0167

    Rockville, Maryland, 20852-4219

Other trials in United States

Poland6 sites
  • Teva Investigational Site 060-1104

    Gdansk, 80-542

  • Teva Investigational Site 060-1101

    Katowice, 40-123

  • Teva Investigational Site 060-1105

    Krakow, 31503

  • Teva Investigational Site 060-1102

    Poznan, 60-693

  • Teva Investigational Site 060-1106

    Torun, 87-100

  • Teva Investigational Site 060-1103

    Warsaw, 02-793

Other trials in Poland

Ukraine6 sites
  • Teva Investigational Site 060-2003

    Dnipropetrovsk, 49101

  • Teva Investigational Site 060-2001

    Kharkiv, 61068

  • Teva Investigational Site 060-2002

    Kharkiv, 61153

  • Teva Investigational Site 060-2007

    Kiev, 4080

  • Teva Investigational Site 060-2005

    Kyiv, 4209

  • Teva Investigational Site 060-2006

    Vinnytsia, 21005

Other trials in Ukraine

Argentina5 sites
  • Teva Investigational Site 060-1407

    Buenos Aires, C1023AAB

  • Teva Investigational Site 060-1401

    Buenos Aires, C1058AAJ

  • Teva Investigational Site 060-1402

    Buenos Aires, C1425AHQ

  • Teva Investigational Site 060-1403

    La Plata, 1900

  • Teva Investigational Site 060-1404

    Mendoza, 5500

Other trials in Argentina

Colombia4 sites
  • Teva Investigational Site 060-1503

    Bello, 051050

  • Teva Investigational Site 060-1501

    Medellín, 5500515

  • Teva Investigational Site 060-1506

    Medellín, 78 B 50

  • Teva Investigational Site 060-1504

    Pereira, 660003

Other trials in Colombia

Italy4 sites
  • Teva Investigational Site 060-1005

    Cagliari, 09121

  • Teva Investigational Site 060-1001

    Catania, 95123

  • Teva Investigational Site 060-1003

    Naples, 80131

  • Teva Investigational Site 060-1004

    Rome, 00165

Other trials in Italy

Mexico4 sites
  • Teva Investigational Site 060-1601

    Culiacán, 80020

  • Teva Investigational Site 060-1603

    León, 37000

  • Teva Investigational Site 060-1602

    Monterrey, 64460

  • Teva Investigational Site 060-1604

    Monterrey, 64610

Other trials in Mexico

South Korea4 sites
  • Teva Investigational Site 060-1901

    Seoul, 110-744

  • Teva Investigational Site 060-1903

    Seoul, 138-736

  • Teva Investigational Site 060-1904

    Seoul, 3722

  • Teva Investigational Site 060-1902

    Seoul, 6351

Other trials in South Korea

Australia2 sites
  • Teva Investigational Site 060-1802

    Liverpool, 2170

  • Teva Investigational Site 060-1801

    Parkville, 3052

Other trials in Australia

Hungary2 sites
  • Teva Investigational Site 060-0901

    Budapest, 1021

  • Teva Investigational Site 060-0902

    Szeged, 6725

Other trials in Hungary

About this study

Official title: A Well-Controlled, Fixed-Dose Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tics Associated With Tourette Syndrome

Standard placebo-controlled, double-blind study design (TEV-50717 [low dose and high dose] vs. placebo in a 1:1:1 ratio) was chosen to determine whether study drug treatment results in a statistically significant effect on the tics in participants with TS.

Being tested
TEV-50717, Placebo
Medical subject headings
Tourette Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TEV-50717Drug

    Also called AUSTEDO, Deutetrabenazine

    6-, 9-, 12-, 15-, and 18 mg oral tablets

  • PlaceboDrug

    Placebo matched to TEV-50717 tablets will be taken BID.

Study groups in NCT03571256
Study groupRoleWhat they receive
TEV-50717 High-DoseExperimentalTEV-50717 tablets twice daily (BID) up to 48 milligrams (mg)/day orally for a total of 8 weeks
Receives: Drug: TEV-50717; Drug: Placebo
TEV-50717 Low-DoseExperimentalTEV-50717 tablets BID up to 36 mg/day orally for a total of 8 weeks
Receives: Drug: TEV-50717; Drug: Placebo
PlaceboPlacebo comparatorPlacebo matched to TEV-50717 for a total of 8 weeks
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in the TTS of the YGTSS at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants

    YGTSS rating scale is a semi-structured clinician rating instrument that provides an evaluation of the number, frequency, intensity, complexity, and interference of motor and phonic tics. YGTSS is composed of 11 items: 5 items for motor tic severity, 5 items for vocal tic severity, and 1 item for impairment. Each item for motor tic severity and vocal is rated on a 6-point scale (0 for none to 5 to severe). MTSS is the sum of the 5 items for motor tic severity and VTSS is the sum of the 5 items for vocal tic severity. TTS is the sum of MTSS and VTSS, ranges from 0 (none/absent) to 50 (severe). Higher scores indicate greater severity/worse outcome. Least square (LS) mean and standard error (SE) was calculated using mixed-model repeated-measures (MMRM) with treatment group, week (3 levels: Weeks 2, 4, and 8), and the treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6 to 11 years, 12 to 16 years) as covariates.

    Measured: Baseline, Week 8

Secondary outcomes (9)
  1. Change From Baseline in the Tourette Syndrome-Clinical Global Impression (TS-CGI) Score at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants

    The TS-CGI scale is a 7-point Likert scale that allows the clinician to use all available information to assess the impact of tics on the participant's quality of life. The TS-CGI is rated as follows: 1 (normal or no tics at all), 2 (borderline), 3 (mild), 4 (moderate), 5 (marked), 6 (severe), and 7 (extreme, incapacitating tics). Lower scores indicate better quality of life. LS mean and SE was calculated using MMRM with treatment group, week (3 levels: Weeks 2, 4, and 8), and the treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6 to 11 years, 12 to 16 years) as covariates.

    Measured: Baseline, Week 8

  2. Change From Baseline in the TTS of the YGTSS at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants

    YGTSS rating scale is a semi-structured clinician rating instrument that provides an evaluation of the number, frequency, intensity, complexity, and interference of motor and phonic tics. YGTSS is composed of 11 items: 5 items for motor tic severity, 5 items for vocal tic severity, and 1 item for impairment. Each item for motor tic severity and vocal is rated on a 6-point scale (0 for none to 5 to severe). MTSS is the sum of the 5 items for motor tic severity and VTSS is the sum of the 5 items for vocal tic severity. TTS is the sum of MTSS and VTSS, ranges from 0 (none/absent) to 50 (severe). Higher scores indicate greater severity/worse outcome. LS mean and SE was calculated using MMRM with treatment group, week (3 levels: Weeks 2, 4, and 8), and the treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6 to 11 years, 12 to 16 years) as covariates.

    Measured: Baseline, Week 8

  3. Change From Baseline in the TS-CGI Score at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants

    The TS-CGI scale is a 7-point Likert scale that allows the clinician to use all available information to assess the impact of tics on the participant's quality of life. The TS-CGI is rated as follows: 1 (normal or no tics at all), 2 (borderline), 3 (mild), 4 (moderate), 5 (marked), 6 (severe), and 7 (extreme, incapacitating tics). Lower scores indicate better quality of life. LS mean and SE was calculated using MMRM with treatment group, week (3 levels: Weeks 2, 4, and 8), and the treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6 to 11 years, 12 to 16 years) as covariates.

    Measured: Baseline, Week 8

  4. Change From Baseline in the Tourette Syndrome-Patient Global Impression of Impact (TS-PGII) Score at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants

    The TS-PGII is a single-item questionnaire that asks the participant to assess the degree of impact due to current tics (How much do your current tics disrupt things in your life?). The TS-PGII uses a 5-point scale, ranging from not at all (1) to very much (5), to assess overall response to therapy.

    Measured: Baseline, Week 8

  5. Change From Baseline in the TS-PGII Score at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants

    The TS-PGII is a single-item questionnaire that asks the participant to assess the degree of impact due to current tics (How much do your current tics disrupt things in your life?). The TS-PGII uses a 5-point scale, ranging from not at all (1) to very much (5), to assess overall response to therapy.

    Measured: Baseline, Week 8

  6. Change From Baseline in the Child and Adolescent Gilles de la Tourette Syndrome - Quality of Life (C&A-GTS-QOL) Activities of Daily Living (ADL) Subscale Score at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants

    C\&A-GTS-QOL is a 27-item questionnaire that asks participant to assess the extent to which their quality of life is impacted by their symptoms. C\&A-GTS-QOL contains 6 subscales (cognitive, coprophenomena, psychological, physical, obsessive-compulsive, and ADL) and uses a 5-point Likert scale ranging from no problem to extreme problem. Following 3 questions from 27-item questionnaire were assessed in ADL C\&A-GTS-QOL subscale: Question 2 (Had difficulty with school or sport activities?), 24 (Felt you needed more help or support from other people?), and 26 (Had difficulty going out with other people?). Total score of ADL subscale ranged from 0 (no problem) to 12 (extreme problem). Lower score indicated better quality of life. LS mean and SE was calculated using MMRM with treatment group, week (3 levels: Weeks 2, 4, and 8), and treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6-11 years, 12-16 years) as covariates.

    Measured: Baseline, Week 8

  7. Change From Baseline in the C&A-GTS-QOL ADL Subscale Score at Week 8 Between Low-Dose TEV-50717-Treated Participants and Placebo-Treated Participants

    C\&A-GTS-QOL is a 27-item questionnaire that asks participant to assess the extent to which their quality of life is impacted by their symptoms. C\&A-GTS-QOL contains 6 subscales (cognitive, coprophenomena, psychological, physical, obsessive-compulsive, and ADL) and uses a 5-point Likert scale ranging from no problem to extreme problem. Following 3 questions from 27-item questionnaire were assessed in ADL C\&A-GTS-QOL subscale: Question 2 (Had difficulty with school or sport activities?), 24 (Felt you needed more help or support from other people?), and 26 (Had difficulty going out with other people?). Total score of ADL subscale ranged from 0 (no problem) to 12 (extreme problem). Lower score indicated better quality of life. LS mean and SE was calculated using MMRM with treatment group, week (3 levels: Weeks 2, 4, and 8), and treatment group by week interaction as fixed effects; and baseline TTS, region, and age group at baseline (2 levels: 6-11 years, 12-16 years) as covariates.

    Measured: Baseline, Week 8

  8. Change From Baseline in the Children's Depression Inventory Second Edition (CDI-2; Parent Version and Self-reported Version) Total Score at Week 9

    CDI-2 self-report: 28-item questionnaire assessing depressive symptoms in children 7 to 17 years of age with basic reading and comprehension skills. Children were asked to choose 1 of 3 statements that most closely aligns with their feelings in past 2 weeks. It contains 6 subscales (emotional problem, negative mood/physical symptoms, negative self-esteem, functional problems, ineffectiveness, interpersonal problems). Total score: sum of all subscales scores, ranging from 0 to 56, with higher score indicating greater depression severity.CDI-2 parent: 17-item questionnaire administered to parents to assess depression-related behaviors observed in their children. Parents were asked to rate their child's behaviors in past 2 weeks on a 4-point Likert scale from "not at all" to "much or most of the time." It contains 2 subscales (emotional problems and functional problem). Total score: sum of 2 subscales, ranging from 0 to 51, with higher score indicating more depression-related behaviors.

    Measured: Baseline, Week 9

  9. Number of Participants at Baseline and Week 9 With Any Suicidal Ideation or Suicidal Behavior According to the Columbia Suicide Severity Rating Scale (C-SSRS)

    C-SSRS included responses for Suicidal Ideation or Suicidal Behavior in following 10 categories: 1 = Wish to be dead; 2 = Non-specific active suicidal thoughts; 3 = Active suicidal ideation with any methods (not plan) without intent to act; 4 = Active suicidal ideation with some intent to act, without specific plan; 5 = Active suicidal ideation with specific plan and intent; 6 = Preparatory acts or behavior; 7 = Aborted attempt; 8 = Interrupted attempt; 9 = Non-fatal suicide attempt; and 10 = Completed suicide. Number of participants with any suicidal ideation or suicidal behavior are reported. Any Suicidal ideation or Suicidal Behavior events reported as TEAEs along with all other reported TEAEs are included in the AE module.

    Measured: Baseline, Week 9

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jun 2018
  2. Study start31 May 2018
  3. Primary completion9 Dec 2019
  4. Study completion9 Dec 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
158 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03571256
Sponsor's protocol ID
TV50717-CNS-30060
Other IDs
2017-002976-24, 2017
Acronym
ARTISTS2
Status last verified
Nov 2021
First submitted
18 Jun 2018
Last updated
9 Nov 2021
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be reviewed for scientific merit, product approval status, and conflicts of interest. Patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.

Publications

  • Coffey B, Jankovic J, Claassen DO, Jimenez-Shahed J, Gertz BJ, Garofalo EA, Stamler DA, Wieman M, Savola JM, Gordon MF, Alexander JK, Barkay H, Harary E. Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial. JAMA Netw Open. 2021 Oct 1;4(10):e2129397. doi: 10.1001/jamanetworkopen.2021.29397.

    PubMed 34661664

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing TEV-50717 in people with Tourette Syndrome, run by Teva Branded Pharmaceutical Products R&D, Inc. at 56 sites in 10 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 56 sites in United States, Poland, Ukraine, Argentina, Colombia and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 9 Jun 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in the TTS of the YGTSS at Week 8 Between High-Dose TEV-50717-Treated Participants and Placebo-Treated Participants (time frame: Baseline, Week 8). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03571256, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Nov 2021.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
ARTISTS2 Clinical Trial NCT03571256 | AzTrials